Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REASON: Guselkumab in Crohn's Disease
NCT06408935Phase 3Active, not recruiting
- Sponsor
- Janssen-Cilag
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of guselkumab in Crohn's disease, sponsored by Janssen-Cilag. Started Apr 2024; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06408935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408935.